EU Commission unlocks health funds but leaves civil society reeling from cuts
The publication ended months of uncertainty and delay, with deep funding cuts already severely impacting NGOs and civil society groups operating in the health sector.
A Commission spokesperson attributed the delay to several factors including the transition to the new Commission that took office in December 2024 and digestion of updated mission letters for commissioners, which came in September last year.
The need to adjust for earlier budget reallocations was also cited, notably a €1 billion diversion from EU4Health to support Ukraine, announced in February 2024.
But more troubling for health NGOs is what the new programme confirms: a complete elimination of operating grants - funds that support an organisation's core operations - leaving only action grants, which finance specific projects.
'It does not mean that NGOs will not be able to directly participate. It's just that we are doing the funding now differently,' a Commission spokesperson told Euronews, referring to this new focus on action grants rather than operational ones.
But for these organisations, what may appear to be a mere bureaucratic adjustment actually represents a significant structural shift, as much of their core work—such as on digital health and air pollution—does not easily fit into isolated, time-limited projects.
Civil society left in 'survival mode'
The delay to unveiling the work programme left health civil society organisations already unable to plan or secure interim financing, resulting in staff reductions and suspended operations.
'The absence of operating grants has pushed many in our sector into survival mode, especially for us, as a large organisation that has historically relied on them,' Milka Sokolović, director general of the European Public Health Alliance (EPHA), told Euronews.
As one of the largest health-focused civil society groups in Europe, EPHA has been forced to cut its staff by 40% this year due to the uncertainty and reduced funding.
It's not alone. EURORDIS, the European organisation representing patients with rare diseases, also criticised the cuts.
'It's deeply regrettable that the EU4Health 2025 Work Programme not only confirms the exclusion of operating grants for health NGOs, but also provides few – if any – alternative funding opportunities for civil society,' said Virginie Bros-Facer, CEO of EURORDIS.
"Over the past 20 years, DG SANTE [the Commission's health service] has recognised the value of operating grants as the only funding mechanism that ensures meaningful interaction between civil society and EU institutions," said Florence Berteletti from the European Alcohol Policy Alliance.
She added that operating grants represent only a marginal share of the EU health budget—just 1%.
With cuts in operating grants, many of these NGOs are expected to struggle to stay afloat, as they will no longer be able to fulfil essential roles.
EU, a shrinking space for civil society
The funding shortfall comes amid broader concerns that civil society is being sidelined.
Right-wing criticism of the Commission's funding of environmental NGOs has created a climate some see as increasingly hostile to non-profit organisations.
For Sokolović, the Commission's funding of NGOs exists to balance the influence of wealthier private lobbies.
'It allows us to act as watchdogs for democracy at a time of democratic backsliding. Without it, commercial interests will dominate EU decision-making, unchecked. And I must say — this goes far beyond health,' she said.
The other trend is a reduced space for health actions in the EU's priorities compared to the launch of EU4Health in the wake of the COVID-19 pandemic, designed as the EU's first standalone health budget, with €5.3 billion allocated to strengthen the sector.
But five years on, and in the absence of core support for NGOs, many are now questioning whether public health remains a true EU priority.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
3 days ago
- Euronews
EU regulators back climate-friendly inhaler
European regulators have given their backing to a new eco-friendly inhaler that could help curb health care's climate impact. Drugmaker AstraZeneca said the new inhaler has a fraction of the carbon footprint of its existing model, which uses a gas propellant to deliver a dose of medicine to patients and is already available in the European Union for adults with chronic obstructive pulmonary disease (COPD). These types of inhalers may be small, but they pack a powerful punch, producing the same type of greenhouse gas as air conditioning and heat pumps. In the United Kingdom, they cause 3 per cent of the National Health Service's (NHS) overall carbon emissions, according to Asthma + Lung UK. Many of these gases are now being phased out in the EU for environmental reasons, according to the European Medicines Agency (EMA). An EMA advisory committee issued a positive opinion of the new inhaler on Friday, and the European Commission, the EU's executive body, will make a final decision in the coming months. Other inhalers that do not use gas propellants are already available, and AstraZeneca's new model has a similarly low carbon footprint. The new option 'means patients and their clinicians now don't need to feel like they have to choose between the most appropriate treatment and the planet,' Pablo Panella, AstraZeneca's senior vice president of global respiratory and immunology, said in a written comment to Euronews Health. The new inhaler is already available in the United States, China, and Japan, and the United Kingdom signed off in May. AstraZeneca said it plans to transition its inhalers to the new model across the EU in the coming months, and that it hopes to roll the model out worldwide by 2030. The EMA said it 'works the same way and gives the same results in the lungs and the body [as] the product currently on the market'.
Euronews
3 days ago
- Euronews
EU regulator backs new Alzheimer's drug, months after rejecting it
The European Union's medicines regulator is reversing course on its decision to block a new Alzheimer's disease treatment, saying the drug can be offered to certain patients under strict safety protocols. In late March, the European Medicines Agency's (EMA) drug evaluators said the risks did not outweigh the benefits for the medicine donanemab, which can slow the progression of early-stage Alzheimer's but also raises the risk of potentially deadly brain swelling and bleeding. But in a revised opinion on Friday, the group said donanemab can be offered to a specific subset of Alzheimer's patients in tightly controlled settings. Donanemab, which is sold by Eli Lilly as Kisunla, is a monoclonal antibody taken via a once-monthly infusion. It's already been approved in the United Kingdom, the United States, Japan, and China. In a clinical trial, Kisunla slowed dementia symptoms by up to 35 per cent over 18 months – but three people died with serious amyloid‑related imaging abnormalities (ARIA), which are a common side effect of the medicine that can cause swelling and bleeding in the brain. Two of these patients carried a type of gene that raises the risk of Alzheimer's, and Lilly had suggested that the medicine only be offered to people who do not have the gene. In March, the EMA committee said that people without the gene were still at risk of fatal complications from ARIA. On Friday, the group said the drug can be offered to early Alzheimer's patients who have at most one copy of the gene – but only in a controlled access programme with medical teams that know how to detect and treat ARIA. Patients must also start at a lower dose. The EMA said that with those measures in place, its advisory group 'concluded that Kisunla's benefits outweigh its risks in noncarriers and people with just one copy' of the gene. The European Commission has the final say on whether a new drug or vaccine is approved, but it usually adopts the EMA evaluators' recommendations. That's why drugmaker Lilly had asked the EMA group to reconsider its negative opinion on Kisunla. It argued that ARIA is usually temporary and does not cause symptoms in most cases. Alzheimer's groups were also disappointed by the initial decision. At the time, Alzheimer Europe said that while patient safety is important, strict prescribing rules and safety monitoring could help ensure dementia patients have access to the new drug while keeping it away from those at higher risk of serious side effects. Notably, the EMA and the Commission recently greenlit another Alzheimer's drug, Leqembi, that comes with similar side effects for people with the gene. In that case, the EMA group had also first refused the drug, but later recommended that it be offered to people with only one or no copies of the gene – making it the first medicine of its kind authorised in the EU. The Commission is expected to make a final decision on Kisunla in the coming months.
Euronews
3 days ago
- Euronews
EU Commission unlocks health funds but leaves civil society reeling from cuts
The European Commission this week finally unveiled its 2025 work programme for its €571 million health budget, EU4Health—a flagship initiative launched in response to the COVID-19 pandemic to strengthen public health across the bloc. The publication ended months of uncertainty and delay, with deep funding cuts already severely impacting NGOs and civil society groups operating in the health sector. A Commission spokesperson attributed the delay to several factors including the transition to the new Commission that took office in December 2024 and digestion of updated mission letters for commissioners, which came in September last year. The need to adjust for earlier budget reallocations was also cited, notably a €1 billion diversion from EU4Health to support Ukraine, announced in February 2024. But more troubling for health NGOs is what the new programme confirms: a complete elimination of operating grants - funds that support an organisation's core operations - leaving only action grants, which finance specific projects. 'It does not mean that NGOs will not be able to directly participate. It's just that we are doing the funding now differently,' a Commission spokesperson told Euronews, referring to this new focus on action grants rather than operational ones. But for these organisations, what may appear to be a mere bureaucratic adjustment actually represents a significant structural shift, as much of their core work—such as on digital health and air pollution—does not easily fit into isolated, time-limited projects. Civil society left in 'survival mode' The delay to unveiling the work programme left health civil society organisations already unable to plan or secure interim financing, resulting in staff reductions and suspended operations. 'The absence of operating grants has pushed many in our sector into survival mode, especially for us, as a large organisation that has historically relied on them,' Milka Sokolović, director general of the European Public Health Alliance (EPHA), told Euronews. As one of the largest health-focused civil society groups in Europe, EPHA has been forced to cut its staff by 40% this year due to the uncertainty and reduced funding. It's not alone. EURORDIS, the European organisation representing patients with rare diseases, also criticised the cuts. 'It's deeply regrettable that the EU4Health 2025 Work Programme not only confirms the exclusion of operating grants for health NGOs, but also provides few – if any – alternative funding opportunities for civil society,' said Virginie Bros-Facer, CEO of EURORDIS. "Over the past 20 years, DG SANTE [the Commission's health service] has recognised the value of operating grants as the only funding mechanism that ensures meaningful interaction between civil society and EU institutions," said Florence Berteletti from the European Alcohol Policy Alliance. She added that operating grants represent only a marginal share of the EU health budget—just 1%. With cuts in operating grants, many of these NGOs are expected to struggle to stay afloat, as they will no longer be able to fulfil essential roles. EU, a shrinking space for civil society The funding shortfall comes amid broader concerns that civil society is being sidelined. Right-wing criticism of the Commission's funding of environmental NGOs has created a climate some see as increasingly hostile to non-profit organisations. For Sokolović, the Commission's funding of NGOs exists to balance the influence of wealthier private lobbies. 'It allows us to act as watchdogs for democracy at a time of democratic backsliding. Without it, commercial interests will dominate EU decision-making, unchecked. And I must say — this goes far beyond health,' she said. The other trend is a reduced space for health actions in the EU's priorities compared to the launch of EU4Health in the wake of the COVID-19 pandemic, designed as the EU's first standalone health budget, with €5.3 billion allocated to strengthen the sector. But five years on, and in the absence of core support for NGOs, many are now questioning whether public health remains a true EU priority.
